Company news

Tasly Pharmaceutical Group Co. Ltd. Class A (SSE:600535) news

Tasly Pharmaceutical Group Co. Ltd. Class A news releases on 6ix. Latest, Sep 25, 2026: "TASLY PHARMACEUTICAL GROUP CO., LTD."Announcement on Resolutions…

View Tasly Pharmaceutical Group Co. Ltd. Class A →

Press releases & updates

"TASLY PHARMACEUTICAL GROUP CO., LTD."Announcement on Resolutions of the 25th Meeting of the 9th Board of Directors

September 24, 2026

"TASLY PHARMACEUTICAL GROUP CO., LTD."Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2026

September 11, 2026

"TASLY PHARMACEUTICAL GROUP CO., LTD."Announcement on Attending the 2026 Online Collective Reception Day for Investors of Listed Companies in Tianjin Jurisdiction

August 28, 2026

"TASLY PHARMACEUTICAL GROUP CO., LTD."Announcement on Convening the 2026 Semi-annual Performance Briefing

August 27, 2026

"TASLY PHARMACEUTICAL GROUP CO., LTD."Announcement on Subsidiary Obtaining the Notice of Approval for Clinical Trial

August 21, 2026

"TASLY PHARMACEUTICAL GROUP CO., LTD."Announcement on Amendments to the Articles of Association

August 10, 2026

"TASLY PHARMACEUTICAL GROUP CO., LTD."Announcement on a Wholly-owned Subsidiary's Receipt of Clinical Trial Notice for the Extension of the Treatment Time Window for the Acute Ischemic Stroke Indication of Recombinant Human Pro-urokinase for Injection

July 17, 2026

"TASLY PHARMACEUTICAL GROUP CO., LTD."Announcement on Semi-annual Performance for 2026

July 14, 2026

Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026

June 25, 2026

Announcement on Obtaining Drug Registration Certificate by Subsidiary

June 15, 2026

Announcement on Remuneration Plan for Directors and Senior Management Members in 2026

June 8, 2026

Announcement on Implementation of Dividend Distribution for 2025

May 21, 2026

Announcement on Convening Performance Briefing for 2025 and Q1 2026

May 18, 2026

Announcement on Change of Accounting Policies

April 24, 2026

Announcement on Resolutions of the 2025 Annual General Meeting

April 17, 2026

Announcement on Guarantee Estimate for 2026

March 23, 2026

Announcement on Annual Key Operating Data Report for 2025

March 19, 2026

Announcement on Resignation of Senior Management Member

March 6, 2026

Preliminary Earnings Estimate for 2025

February 6, 2026

Landmark FDA Move: First Quality Control Protocol for Mesenchymal Stromal Cells (MSCs) Sets New Therapeutic Standard

January 24, 2026

Announcement on Resolutions of the 6th Extraordinary General Meeting in 2025

December 26, 2025

Announcement on Estimated Related Party Transactions of Daily Operations in 2026

December 9, 2025

Announcement on Convening the Q3 2025 Performance Briefing

November 26, 2025

Announcement on Resolutions of the 15th Meeting of the 9th Board of Directors

October 24, 2025

Announcement on Obtaining Drug Registration Certificate for Wenjing Decoction Granules

October 13, 2025

Announcement on Resolutions of the 5th Extraordinary General Meeting in 2025

October 10, 2025

Announcement on Implementation of Semi-annual Dividend Distribution for 2025

October 9, 2025

Announcement on Obtaining Notice of Approval for Drug Clinical Trial

September 24, 2025

Announcement on Acquisition of Drug Registration Certificate for New Indication of Acute Ischemic Cerebral Stroke of the Wholly-owned Subsidiary's Reocmbinant Human Prourokinase for Injection

September 22, 2025

Announcement on Using Idle Funds to Purchase Bank Financial Products

September 17, 2025

Announcement on Progress in Providing Guarantee for Subsidiary

September 15, 2025

Announcement on Attending 2025 Online Collective Reception Day for Investors of Listed Companies in Tianjin Jurisdiction

September 5, 2025

Announcement on Resolutions of the 13th Meeting of the 9th Board of Directors

September 2, 2025

Announcement on Convening the 2025 Semi-annual Performance Briefing

August 20, 2025

2025 Semi-annual Report

August 15, 2025

Announcement on Appointment of Senior Management Members

August 6, 2025

Announcement on Expiration of Duration and Termination of the Employee Stock Ownership Plan

July 23, 2025

Announcement on the Progress of Drug Registration Application

July 18, 2025

Announcement on Resolutions of the 10th Meeting of the 9th Board of Directors

July 15, 2025

Announcement on Obtaining Drug Registration Certificate for D-Glucosamine Sulfate Capsules by Wholly-owned Subsidiary

June 10, 2025

Announcement on Obtaining Drug Registration Certificate for Torasemide Injection by Wholly-owned Subsidiary

May 28, 2025

Announcement on Resolutions of the 3rd Extraordinary General Meeting in 2025

May 14, 2025

Announcement on Resolution of the 2nd Extraordinary General Meeting in 2025

May 7, 2025

Announcement on Key Operating Data for Q1 2025

April 28, 2025

Announcement on Resolutions of the 6th Meeting of the 9th Board of Supervisors

April 15, 2025

Announcement on Election of Employee Director

April 14, 2025

Announcement on Amending the "Articles of Association"

March 28, 2025

Announcement on Resignation of Some Directors and Supervisors

March 27, 2025

Announcement on Implementation of Annual Dividend Distribution in 2024

March 19, 2025

Announcement on Resolution of the 2024 Annual General Meeting

March 17, 2025

Older →